In NSCLC patients with strong PD-L1 expression and tumor proportion scores (TPS) ≥50%, single ICI therapy with pembrolizumab, atezolizumab, or cemiplimab has shown good treatment response rates (of 35–45%) in previous clinical trials (KEYNOTE-024, IMpower110, and EMPOWER-Lung 1) [22,28,32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.